San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...

The FDA had previously turned back the heart rhythm nasal spray twice, once in late 2023 with a refusal to file letter and ...

Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...

For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

A report from analysts at Jefferies suggested that new screenings for metachromatic leukodystrophy and Duchenne muscular dystrophy could bump sales of the gene therapy Libmeldy by more than $100 ...

Ambros Therapeutics’ non-opioid bisphosphonate analgesic, already approved in Italy, will soon begin a pivotal test in the ...

Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in ...